Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 205Unknown 77Recruiting 72Active not recruiting 45Terminated 44Not yet recruiting 21Withdrawn 10Enrolling by invitation 2Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Neoplasms 35Breast Neoplasms 30Prostatic Neoplasms 22Leukemia, Myeloid, Acute 20Colorectal Neoplasms 20Melanoma 17Pancreatic Neoplasms 16Glioblastoma 16Carcinoma, Non-Small-Cell Lung 16Neoplasm Metastasis 15Lung Neoplasms 13Brain Neoplasms 13Glioma 12Stomach Neoplasms 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 11Myelodysplastic Syndromes 11Carcinoma, Hepatocellular 11Ovarian Neoplasms 10Multiple Myeloma 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Lymphoma 8Carcinoma, Renal Cell 8Leukemia 7Sarcoma 6Rectal Neoplasms 6Hematologic Neoplasms 6Esophageal Neoplasms 6Uterine Cervical Neoplasms 5Recurrence 5

Interventions

lenvatinib 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Interventional × Thyroid Neoplasms × Clear all
NCT03139747 2021-10-15

UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib Alone

Thomas Jefferson University

Phase 2 Suspended
5 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡